Tango Therapeutics Inc
$ 27.07
-6.66%
07 Aug - close price
- Market Cap 4,407,393,000 USD
- Current Price $ 27.07
- High / Low $ 29.23 / 26.75
- Stock P/E N/A
- Book Value 2.72
- EPS -0.83
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.38 %
- 52 Week High 34.39
- 52 Week Low 6.25
About
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies. With a robust pipeline of promising drug candidates focused on precision oncology, the company is uniquely positioned to address critical unmet needs in cancer care. Strategic collaborations with top academic institutions bolster its research and development efforts, enhancing its ability to deliver transformative therapeutic solutions. Tango Therapeutics aims to significantly improve patient outcomes and redefine treatment paradigms in oncology, making it a compelling investment opportunity in the biopharmaceutical landscape.
Analyst Target Price
$44.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-05 | 2025-11-04 | 2025-08-05 | 2025-05-12 | 2025-02-27 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-03-18 | 2023-11-08 | 2023-08-07 |
| Reported EPS | -0.32 | -0.29 | 0.13 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 |
| Estimated EPS | -0.2967 | -0.33 | -0.07 | -0.34 | -0.35 | -0.3428 | -0.37 | -0.35 | -0.31 | -0.28 | -0.34 | -0.34 |
| Surprise | -0.0233 | 0.04 | 0.2 | -0.01 | -0.01 | 0.0028 | 0.1 | 0.11 | -0.04 | -0.04 | 0.11 | 0.11 |
| Surprise Percentage | -7.8531% | 12.1212% | 285.7143% | -2.9412% | -2.8571% | 0.8168% | 27.027% | 31.4286% | -12.9032% | -14.2857% | 32.3529% | 32.3529% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNGX
2026-08-08 00:40:44
This article announces that Tango Therapeutics Inc. filed a Form 8K on August 7th. It is a brief financial news update from Investing.com, highlighting the filing with the Securities and Exchange Commission (SEC). The article also notes a 6.66% decline in Tango Therapeutics' stock symbol TNGX.
2026-08-07 22:40:21
Tango Therapeutics announced that Executive Chair Dr. Barbara Weber's employment ended on August 3, 2026, and she resigned from all positions without disagreement. Her departure aligns with an amended employment agreement, and she will receive a separation package including salary continuation, COBRA reimbursement, and accelerated equity vesting. This transition is presented as an orderly contractual change, aiming to assure investors of governance stability amidst her departure.
2026-08-07 21:40:21
Tango Therapeutics (NASDAQ:TNGX) experienced a 6.1% decline in its share price during midday trading, closing at $27.24 with a significant 86% decrease in trading volume compared to its average. Despite the drop, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $42.15. The company recently met earnings per share expectations, and institutional investors hold a substantial portion of its shares, although an insider recently sold a considerable block of stock.
2026-08-07 21:40:20
Tango Therapeutics (NASDAQ: TNGX) has detailed the separation agreement with its former Executive Chair, Dr. Barbara Weber, whose employment and board roles ended on August 3, 2026. The agreement, executed on August 6, 2026, includes base-salary severance and COBRA reimbursement through December 31, 2026, full acceleration of outstanding options and RSUs, and a pro-rata 2026 annual incentive. These benefits are conditional upon her not revoking the agreement.
2026-08-07 14:16:35
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that Dr. Barbara Weber, Executive Chairman of its Board of Directors, will be stepping down to pursue other interests. The company expressed gratitude for her vision, leadership, and commitment. Tango Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines using the principle of synthetic lethality.
2026-08-07 12:46:00
This article announces that Tango Therapeutics Inc. filed a Form 8K on August 7. The filing is brief, simply stating the company name and the filing date, and does not provide further details within the article content.
